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e-mail address: dr_begum@hotmail.com (B.B. Kilic).Begum Bulam Kilic a,⇑; Dilek Dursun Altiors b; Muge Demirbilek b; Ersin Ogus bAbstractPurpose: This study was conducted to investigate the effects of an experimental bacterial keratitis model on the corneal collagen
cross-linking treatment (CXL), and also to compare topical antibiotic treatment with the combined treatment.
Methods: The study involved 40 young adult female Sprague Dawley rats, which had a 2 mm scraped defect of the central corneal
epithelium in both eyes. The rats were divided into two equal groups. The first group was inoculated in both eyes with standard
Pseudomonas Aeruginosa (PA) from a strain suspension prepared from 0.05 ml (Group 1), and the second group was inoculated
with standard Methicillin Resistance Staphylococcus Aureus (MRSA) strains from a suspension prepared from 0.05 ml (Group 2).
Group 1 was divided into four sub-groups: Group 1A was treated by collagen cross-linking (CXL), Group 1C was treated with topi-
cal tobramycin drops CXL and also treated by collagen cross-linking (CXL), Group 1D was treated with topical tobramycin drops,
and Group 1B was left untreated in order to create a control group. Similarly, Group 2 was also divided into four sub-groups:
Group 2A was treated by CXL, Group 2C was treated with topical 5% fortified vancomycin drops CXL and also treated by
CXL, Group 2D was treated with topical 5% fortified vancomycin drops, and Group 2B was left untreated in order to create a con-
trol group. CXL was performed on the third day following the inoculation and topical drop therapy. Biomicroscopy and microbi-
ologic assessments were performed on the third and seventh days following the inoculation of microorganisms.
Results: In the treatment, which compared baselines in all groups before treatment, the diameter of keratitis infiltrations, corneal
clouding, and corneal swab samples were obtained from the reduction in reproduction. The results were statistically significant
(p < 0.01). Keratitis infiltration groups were conducted on the seventh day for Groups 1C and 1D according to Group 1B, whilst
Groups 2A, 2C and 2D were conducted according to Group 2B, which showed a significant statistical reduction (p < 0.01). On the
seventh day, focal groups were conducted in corneal clouding Group 1D according to Group 1B and in Groups 2A, 2C and 2D
according to Group 2B, which revealed a significant statistical reduction (p < 0.01). On the seventh day, reproduction in culture
was obtained from corneal swab samples in Groups 1C and 1D according to Group 1B; in Groups 1C and 1D according to Group
1A; in Groups 2A, 2C and 2D according to Group 2B; and in Group 2C according to Group 2A, where a significant statistical
reduction was observed (p < 0.01).
Conclusions: The clinical and microbiological efficacy of the CXL treatment is evaluated in our study. In accordance with the
conclusion reached an effective reduction in the density and severity of (infection), occurred as a result of CXL treatment, CXL
treatment combined with topical antibiotic treatment and topical antibiotic treatment of Pseudomonas Aeruginosa (PA) and
Metisilin Rezistant Staphylococcus Aureus (MRSA) keratitis infections. From these results, it is shown that topical antibiotics and
CXL potentiate each other’s effects in the treatment of resistant bacterial keratitis.
Keywords: Cornea, Bacterial Keratitis, Cross-linking
 2017 Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.sjopt.2017.10.003e:
al.com
98 B.B. Kilic et al.Introduction
It is currently common practice to treat corneal infections
with a broad range of antibiotics but, as the medical profes-
sion is faced with the problem of increased bacterial resis-
tance to antibiotic medication, the need to introduce
alternative treatments is becoming an issue of growing signif-
icance.1 This is particularly crucial when considering corneal
infections, as serious damage to the patient’s vision, and
even blindness, can ensue, leading to the necessity for more
serious treatments, such as chemotherapy or surgery.
One alternative to antibiotic treatment is known as corneal
collagen crosslinking (CXL). This treatment works by using
UV–A at 365 or 370 nm to activate the photosensitive prop-
erties of riboflavin to initiate photochemical reactions which
result in covalent bonds or crosslinks in the corneal stroma,
which in turn can augment the cornea’s biomechanical
strength and, thus, potentially arrest the further advance-
ment of keratoconus.2,3 The idea of using UV rays against
microorganisms is certainly not new and is regularly found
in research; it is also widely utilised in medical settings such
as operating theatres to augment existing sterilisation
techniques.4,5
The first relevant study in this area was carried out in 1960,
when it was revealed that, upon exposure to UV rays, ribofla-
vin would inactivate the RNA of various viruses. Contempo-
rary studies have found that riboflavin also behaves as a
photomediator and has the capacity to neutralize not only
pathogens in plasma, platelets, and red blood cells6–8 but
also a variety of viruses, bacteria, and parasites.9
The treatment of corneal infections using CXL confers an
additional benefit, in that resistance of the cornea to enzy-
matic digestion by microorganisms10 is increased.
It is the case that 90% of the thickness of the cornea con-
sists of the stroma, which is made up of collagen fibrils
caught up within an environment of proteoglycans, proteins,
glycoproteins and keratocytes located amid the collagen
lamellae.
Some microorganisms, including bacteria and fungi, emit
enzymes that have the capacity to digest collagen, in turn
leading to melting and perforation of the cornea. Notwith-
standing microbiological remedy, deterioration of collagen
and proteolysis as a result of enzymatic action may well still
be apparent in the form of progressive ulceration. Use of
the CXL treatment in porcine testing has had very positive
results against enzymatic degeneration by collagenase, tryp-
sin and pepsin. It can therefore be supposed that CXL is not
only able to neutralise the microorganisms causing the infec-
tion, but also confer the benefit of corneal rigidity, thereby
lessening vulnerability of the stroma to proteolysis and the
advancement of corneal melt.10–12Material and methods
Preparations of the strains
The standard strains PA ATCC 9027 and MRSA ATCC
33591 were utilized in this study. It was necessary for the
strains to be kept at a temperature of 86 C until required
for testing purposes, at which point they were revived with
agar containing 5% sheep blood; was necessary for them to
be passaged twice with blood agar. The suspensions of thestrains are dense and they were prepared in sterile physiolog-
ical serum. The actual concentration of bacteria required was
1.0  108 CFU/ml in each 50 ll suspension to be introduced
into the rat eyes; this was achieved by means of dilution using
physiological saline solution spectrophotometrically.Animals
The study included 40 young adult female Sprague Daw-
ley rats weighing between 230 and 250 kg. All rats were trea-
ted in accordance with the Association for Research in Vision
and Ophthalmology statement for the use of animal in oph-
thalmic research, and the protocol was approved by the Insti-
tutional Ethics Committee. The rats were anesthetized with
50 mg/kg of intraperitoneal ketamine hydrochloride and 7
mg/kg of xylazine before all interventions. Corneal anesthe-
sia was attained using 0.5% topical proparacaine hydrochlo-
ride. The central corneal epithelium was marked with a 2
mm disposable dermatological skin punch (Acu-Punch, Acud-
erm, Ft. Lauderdale, FL). The marked corneal epithelium was
scraped using a number 11 scalpel (Fig. 1a). The rats were
divided into two equal groups. The first group was inoculated
into both eyes with standard Pseudomonas Aeruginosa (PA)
from a strain suspension prepared from 0.05 ml (Group 1),
and the second group was inoculated with standard Methi-
cillin Resistance Staphylococcus Aureus (MRSA) strains from
a suspension prepared from 0.05 ml (Group 2) (Fig. 1b).
Three days later, bio microscopic examination revealed ker-
atitis in both eyes of all rats. All rats were swallowed from
the cornea of both eyes and microbiologically appeared to
be infected.
Group 1 was divided into four sub-groups: Group 1A was
treated by collagen cross-linking (CXL), Group 1C was trea-
ted with topical tobramycin drops (CXL) and also treated
by collagen cross-linking (CXL), Group 1D was treated with
topical tobramycin drops, and Group 1B was left untreated
in order to create a control group. Similarly, Group 2 was also
divided into four sub-groups: Group 2A was treated by CXL,
Group 2C was treated with topical 5% fortified vancomycin
drops (CXL) and also treated by (CXL), Group 2D was treated
with topical 5% fortified vancomycin drops, and Group 2B
was left untreated in order to create a control group
(Table 1).Treatment
The CXL procedure was performed three days after the
inoculation of Pseudomonas Aeruginosa (PA) and Methicillin
Resistance Staphylococcus Aureus (MRSA), conducted under
sterile conditions in an operating room. Topical drop therapy
was undertaken within those groups which were exposed to
CXL treatment after CXL (on the third day), and no CXL treat-
ment (only topical antibiotics treatment the third day after
introduction of the microorganism suspension). The rats were
anesthetized with intramuscular 50 mg/kg of ketamine
hydrochloride and 7 mg/kg of xylazine before all interven-
tions and corneal anesthesia was attained using 0.5% topical
proparacaine hydrochloride. Using a number 11 scalpel, a 2
mm central fragment of the corneal epithelium was carefully
detached. As a photosensitizer, a riboflavin 0.1% solution (10
mg of riboflavin-5-phosphate in 10 mL of dextran–T-500 20%
solution) was applied every five minutes for 30 min before
Fig. 1. (a) Abrasion of the corneal epithelium using a number 11 scalpel. (b) Introduction of microorganism suspension on the created epithelial defect
area.
Table 1. Rats groups’ definition with treatment.
Experimental rats Eye Groups Group definition Group treatment
Rat 1 Left eye Group 1 A Crosslinking Groups Treated by collagen cross-linking (CXL)
Right Eye Group 1 B Control Groups Untreated in order to create a control group
Rat 2 Left eye Group 1 C Crosslinking Groups Treated by collagen cross-linking (CXL), and also
treated with topical tobramycin drops
Right Eye Group 1 D Control Groups Treated with topical tobramycin drops
Rat 1 Left eye Group 2 A Crosslinking Groups Treated by collagen cross-linking (CXL)
Right Eye Group 2 B Control Groups Untreated in order to create a control group
Rat 2 Left eye Group 2 C Crosslinking Groups Treated by collagen cross-linking (CXL), and also
treated with topical tobramycin drops
Right Eye Group 2 D Control Groups Treated with topical tobramycin drops
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(Fig. 2a and b). After allowing the riboflavin to permeate
through the cornea, UV-A irradiation was started. For the
operation, a 370 nm UV light-emitting diode as well as
CBM Vega X-Link equipment with a power density of irradia-
tion of 3 mW/cm2, maximum radiated power of 4 mW, an
irradiated area diameter of 4–11 mm and a single led UV-A
as a UV source were used. The operation was performed
on all eyes in Groups 1A, 1C, 2A and 2C from a distance of
54 mm for 30 min. The cornea of each rat was irradiated by
use of the UV light diodes (370 nm) at a distance of 54 mm
for 30 min using 3 mW/cm2 irradiance; this equals a dose of
5.4 J/cm2.Fig. 2. (a) Introduction of 0.1% riboflavin solution in preparation for irradClinical examination
The eyes were examined on day 0 (bacterial inoculation),
day 3 (prior to undergoing CXL and topical treatment), and
day 7 (four days after CXL and topical treatment) using a por-
table slit-lamp biomicroscope. The extent of keratitis was
evaluated by a masked observer. The diameter of corneal
infiltration and corneal clouding were evaluated using the
modified scoring system of Ozturk et al.13 The diameter of
corneal infiltration was measured in millimeters. Corneal infil-
tration was graded as follows: corneal infiltration is unavail-
able, 0; corneal infiltration < 1.5 mm, 1; corneal infiltration
1.5–3 mm, 2; and corneal infiltration > 3 mm, 3. Cornealiation. (b) Introduction of 0.1% riboflavin solution during irradiation.
100 B.B. Kilic et al.clouding was graded as follows: clear cornea, 0; minor
edema, 1; corneal edema in two quadrants of the cornea,
2; and corneal edema in more than two quadrants of the cor-
nea, 3.
Microbiological analysis
The eyes were examined on day 3 (prior to performing
CXL and topical treatment), and on day 7 (four days after
CXL and topical treatment) corneal swab samples placed into
amies transport medium after anesthesia (as defined above)
were cultivated with 5% sheep blood agar in the laboratory.
The plates were incubated overnight at 37 C and then the
density of reproductions were graded from 0 to 4 using the
following system: no reproduction, 0; an insignificant number
of colonies in the first area, 1; a significant number of colonies
in the first area, 2; reproduction in the second area also, 3;
and dense reproduction extending to the third area, 4.
Statistical analysis
The Statistical Package for Social Sciences (Version 17,
Chicago IL, USA) (SPSS) was utilised to analyse the data
and variables were designated as mean ± standard deviation.
In order to evaluate observance of the data to a repeated
measures analysis of variance, Mauchly’s sphericity test and
Box-M’s test of Homogeneity of Variances was applied.
Repeated measures variance, which was a factor included in
the factorial design, was used to compare the means. Where
preconditions of parametric tests (repeated measures vari-
ance analysis on factorial design) were unfulfilled, the
Greenhouse-Geisser test (1959), correcting the degrees of
freedom, or Huynh-Feldt (1976), were utilized, and the Cor-
rected Bonferroni test was implemented to perform multiple
comparisons. The values p < 0.05 and p < 0.01 were followed
for use in the significance level of the tests.Results
Clinical examination results
By day 3 (72 h after inoculation), it was found that Pseu-
domonas Aeruginosa (PA) and Methicillin Resistance Staphy-
lococcus Aureus (MRSA) keratitis had become established in
all inoculated eyes. At day 0, no statistically significant varia-
tion between groups existed (p > 0.05); however, at day 3,
the diameter of keratitis infiltrations keratitis were statistically
and significantly higher in Group 1C (CXL+ tobramycin) than
in Group 1B (untreated) (p = 0.04). No such statistically signif-
icant difference existed within the remaining groups on day 3
(p > 0.05). Subsequently, a statistically significant reduction
in the diameter of keratitis infiltrations in Groups 1A (CXL),
1C (CXL+ tobramycin), 1D (tobramycin), 2A (CXL), 2C (CXL
+ vancomycin) and 2D (vancomycin) was in evidence after
treatment (day 7) in comparison to that seen prior to treat-
ment (day 3) (p < 0.01) (Fig. 3a and b).
A statistically significant decrease in the diameter of ker-
atitis infiltrations were noted on day 7 between Group 1C,
which had undergone topical tobramycin treatment com-
bined with CXL, and Group 1B (control group), which had
gone untreated (p = .039). Similarly, a decrease was noted
between Group 1D, which had undergone only topicaltobramycin treatment combined with CXL, and Group 1B
(control group), which had gone untreated (p = 0.002). A sta-
tistically significant decrease in the diameter of keratitis infil-
trations were also noted on day 7 between Group 2A, which
had only undergone CXL treatment, and Group 2B (control
group), which had gone untreated (p = 0.001), as well as
between Group 2C, which had undergone topical fortified
vancomycin therapy combined with CXL, and Group 2B (con-
trol group), which had gone untreated (p = 0.001), and also
between Group 2D, which had undergone only topical forti-
fied vancomycin therapy, andGroup 2B (control group), which
had gone untreated (p = 0.001). No statistically significant dif-
ference was found in terms of the diameter of keratitis infiltra-
tions on day 7 between the remaining groups (p > 0.05).
On day 3, prior to the treatment, corneal clouding was
observed to be statistically significant in Group 1A (CXL)
compared to Group 1B (untreated) (p = 0.11) and in Group
1C (CXL+ tobramycin) compared to Group 1B (untreated)
(p = 0.33). No such statistical significance was found on day
3 between the remaining groups (p > 0.05). A statistically sig-
nificant reduction in corneal clouding was observed in
Groups 1A (CXL), 1C (CXL+ tobramycin), 2A (CXL), 2C (CXL
+ vancomycin) and 2D (vancomycin) subsequent to treatment
(day 7) compared to prior to treatment (day 3) (p < 0.01))
(Fig. 4a and b).
Group 1D, which had been treated only with topical tobra-
mycin, exhibited statistically significant deterioration in cor-
neal clouding on day 7 compared to Group 1B (control
group), which had gone untreated (p = 0.004). Group 2A,
which had been treated only with CXL, exhibited a statisti-
cally significant deterioration in corneal clouding on day 7
compared to Group 2B (control group), which had gone
untreated (p = .001), the deterioration was also found in
Group 2C, which had been treated with topical fortified van-
comycin combined with CXL, compared to Group 2B (control
group), which had gone untreated (p = 0.001) and also in
Group 2D, which had been treated with only topical fortified
vancomycin, compared to Group 2B (control group), which
had gone untreated (p = 0.001). No such statistical signifi-
cance was found between the remaining groups on day 7
(p > 0.05) (Fig. 5a–h).Microbiological analysis results
Appraisal of each of the cultures derived from the corneal
swabs taken from the eyes of each of the rats on days 3 and 7
was undertaken. All cultures collected on day 3 exhibited
reproduction. No statistically significant difference in the cul-
tures had existed between the groups within the context of
reproduction prior to the treatment (day 3) (p > 0.05). How-
ever, a statistically significant reduction within the context
of reproduction was in evidence (p < 0.01) subsequent to
treatment (day 7) in contrast to levels in existence before
treatment (day 3) in Groups 1A (CXL), 1C (CXL+ tobramycin),
1D (tobramycin), 2A (CXL), 2C (CXL+ vancomycin) and 2D
(vancomycin) (Fig. 6a and b).
On day 7, statistically significant reductions in the repro-
duction of cultures were observed between Group 1C
(CXL+ tobramycin) and Group 1B (untreated) (p = 0.001),
Group 1D (tobramycin) and Group 1B (untreated)
(p = 0.001), Group 1C (CXL+ tobramycin) and Group 1A
(CXL) (p = 0.001) and Group 1D (tobramycin) and Group 1A
Fig. 3. (a) Group 1 changes in keratitis focus (days 3 and 7). (b) Group 2 changes in keratitis focus (days 3 and 7).
Fig. 4. (a) Group 1 change in corneal edema (days 3 and 7). (b) Group 2 change in corneal edema (days 3 and 7).
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in the reproduction of cultures were also observed between
Group 2A (CXL) and Group 2B (untreated) (p = 0.001), Group
2C (CXL+ vancomycin) and Group 2B (untreated) (p = 0.001),
Group 2D (vancomycin) and Group 2B (untreated) (p = 0.001)
and Group 2C (vancomycin) and Group 2A (CXL) (p = 0.008).
No statistically significant difference in the reproduction of
cultures on day 7 was found to exist between the remaining
groups (p > 0.05).Discussion
Studies relating to in vitro have demonstrated wide-
ranging antimicrobial effects to be gained via the combined
use of riboflavin and UV–A, which has proved effectual in
pre-clinical studies of platelets and plastma against patho-
gens such as bacteria, intracellular human immunodeficiency
virus-1, West Nile virus and porcine parvovirus. It is thought
that the combination of riboflavin and UV–A causes nucleic
acids to degenerate by direct electron transfer, the produc-
tion of singlet oxygen and the generation of hydrogenperoxide with the formation of hydroxyl radicals. It is there-
fore clear that the riboflavin UV-A combination has huge
potential in terms of offering an effective medical treatment
with low protein damage and little toxicity.15
In tests, relief of the symptoms of acanthamoeba keratitis
have been evident within 24 h of the implementation of CXL
treatment, including vision improvement and healing. In
addition, the corneal stability gained via CXL prevents contin-
ued tissue damage and disengages the amoebae, thereby
preventing further spread.16–18 CXL treatment administered
to patients with corneal melt attributable to contact lens
use with infectious keratitis caused by bacteria, fungi, and
acanthamoeba also appears to offer improved healing and
improved overall outcomes, subsequent to such surgical pro-
cedures as corneal transplantation.19
Recent research has been carried out in relation to a sam-
ple of 16 cases of microbial keratitis without prior antibiotic
management. These patients undertook CXL treatment as
their primary mode of treatment. In all cases, abatement of
inflammation and epithelial healing occurred; only two
patients required additional treatment in the form of a stan-
dard topical antibiotic.20
Fig. 5. (a) GROUP 1A before CXL. (b) GROUP 1A after CXL. (c) GRUP 1C before CXL+ Topical Tobramycin. (d) GRUP 1C after CXL+ Topical Tobramycin.
(e) GRUP 2B 3 days after bacterial inoculation. (f) GRUP 2B 7 days after bacterial inoculation. (g) GRUP 2D before Topical vancomycin. (h) GRUP 2D after
Topical vancomycin.
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potent treatment for bacterial corneal infections, it is not
necessarily effective for fungal infection, while, for herpes
simplex keratitis, is potentially best avoided altogether as a
treatment method. Clearly, further study is required further
study into the use of CXL, and comparisons made with ocular
antibiotics for validation purposes; nevertheless, CXL demon-
strates very positive effects and potential benefits in terms of
use on the corneal surface.21As far as side effects are concerned, much research has
shown that CXL with riboflavin treatment gives only minimal
cause for concern. Wollensak et al. undertook a pilot study
on the subject, which noted that corneal and lens trans-
parency, endothelial cell density, and intraocular pressure
all remained unaltered following treatment for keratoconus.3
A further study on the safety of CXL, carried out by Spoerl
et al. to assess possible damage to ocular tissues,22 deter-
mined that no impairment to the corneal endothelium, the
Fig. 6. (a) Group 1 change in reproduction (days 3 and 7). (b) Group 2 change in reproduction (days 3 and 7).
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criteria for the treatment was met.23 Certainly, no serious side
effects were apparent in the CXL group of this study.
The experimental rabbit model of Galperin et al. in rela-
tion to fusarium keratitis assessed CXL with riboflavin in terms
of its clinical and microbiological effectiveness, and reported
that although the treatment is effectual in diminishing the
density and severity of fungal keratitis infection, the treat-
ment is insufficient in cases of fungal keratitis, and therefore
maybe of value only a complementary treatment for fungal
keratitis that is resistant to treatment.1 The experimental rab-
bit model of Berra et al. in relation to acanthamoeba keratitis
assessed CXL with riboflavin in terms of its clinical and micro-
biological effectiveness and reported the treatment to be
ineffectual in diminishing the density and severity of acan-
thamoeba keratitis infection in addition to clinical and micro-
biological degeneration in the affected corneas. In
conclusion, CXL was deemed to be inappropriate in the treat-
ment in acanthamoeba keratitis.16
A publication by Alio et al. concluded that CXL may well
offer an effective contemporary approach to dealing with
infectious keratitis and, in their opinion, the treatment suc-
cessfully controls infectious keratitis by inhibiting corneal
melting. Unfortunately, the lack of availability of control
groups will hinder the further development of this treatment
in the immediate future, although the researchers high-
lighted the potential for studies which compare the applica-
tion of CXL with typical topical antibiotic therapy.24
The clinical and microbiological efficacy of the CXL treat-
ment is evaluated in this study. CXL treatment, CXL treat-
ment combined with topical antibiotic treatment and the
topical antibiotic treatment of Pseudomonas Aeruginosa
(PA) and Metisilin Rezistant Staphylococcus Aureus (MRSA)
keratitis infections led to an effective reduction in the density
and severity (of infection), in accordance with the conclusion
reached by the researchers. From these results, it is shown
that topical antibiotics and CXL potentiate each other’s
effects in the treatment of resistant bacterial keratitis. It is
concluded that these findings should be supported by a
more extensive series of tests and other practices on humans.
Further investigation of this treatment both by in vitro and
in vivo studies, is essential before it can be incorporated into
everyday clinical practice.Conflict of interest
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